Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000561103 | SCV000666520 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-07-16 | criteria provided, single submitter | clinical testing | The p.P694R variant (also known as c.2081C>G), located in coding exon 14 of the NBN gene, results from a C to G substitution at nucleotide position 2081. The proline at codon 694 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001059040 | SCV001223644 | uncertain significance | Microcephaly, normal intelligence and immunodeficiency | 2022-01-27 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 694 of the NBN protein (p.Pro694Arg). This variant is present in population databases (rs746090959, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with NBN-related conditions. ClinVar contains an entry for this variant (Variation ID: 481835). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001059040 | SCV002046065 | uncertain significance | Microcephaly, normal intelligence and immunodeficiency | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004569158 | SCV005056172 | uncertain significance | Aplastic anemia | 2024-01-16 | criteria provided, single submitter | clinical testing |